Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

Bibliography

• Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Demetri G, van Oosterom A, Garrett C, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Motzer R, Hutson T, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Raymond E, Niccoli-Sire P, Bang Y, Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) [abstract #127]. ASCO GI 2010
   Google Scholar
• Mendel D, Laird A, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• Goodman V, Rock E, Dagher R, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
   PubMed Web of Science ®Google Scholar
• Bello C, Sherman L, Zhou J, Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17:353-8
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35
   PubMed Web of Science ®Google Scholar
• Moss K, Toner G, Cherrington J, Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003;307:476-80
   PubMed Web of Science ®Google Scholar
• Baratte S, Sarati S, Frigerio E, Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 2004;1024:87-94
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey R, Bates S, Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-65
   PubMed Web of Science ®Google Scholar
• Houk B, Bello C, Kang D, A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15:2497-506
   PubMed Web of Science ®Google Scholar
• Khosravan R, Toh M, Garrett M, Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010;50:472-81
   PubMed Web of Science ®Google Scholar
• Bello C, Garrett M, Sherman L, Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 2010. [Epub ahead of print]
   Google Scholar
• Faivre S, Raymond E, Boucher E, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800
   PubMed Web of Science ®Google Scholar
• Faivre S, Bouattour M, Dreyer C, Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol 2009;27:e248-50
   PubMed Web of Science ®Google Scholar
• Zhu A, Sahani D, Duda D, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S, Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75
   PubMed Web of Science ®Google Scholar
• Murray L, Abrams T, Long K, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66
   PubMed Web of Science ®Google Scholar
• Abrams T, Murray L, Pesenti E, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-21
   PubMed Web of Science ®Google Scholar
• Morimoto A, Tan N, West K, Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004;23:1618-26
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Periman P, Bernold D, Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21:319
   PubMed Web of Science ®Google Scholar
• Socinski M, Novello S, Brahmer J, Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
   PubMed Web of Science ®Google Scholar
• Burstein H, Elias A, Rugo H, Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-31
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR, Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373-9
   PubMed Web of Science ®Google Scholar
• Saltz L, Rosen L, Marshall J, Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25:4793-9
   PubMed Web of Science ®Google Scholar
• Machiels J, Henry S, Zanetta S, Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-8
   PubMed Web of Science ®Google Scholar
• Mackay H, Tinker A, Winquist E, A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116:163-7
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Heinrich M, Corless C, Duensing A, PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
   PubMed Web of Science ®Google Scholar
• Demetri G, von Mehren M, Blanke C, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali P, Zalcberg J, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
   PubMed Web of Science ®Google Scholar
• Antonescu C, Besmer P, Guo T, Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-90
   PubMed Web of Science ®Google Scholar
• Prenen H, Cools J, Mentens N, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7
   PubMed Web of Science ®Google Scholar
• Parkin D, Bray F, Ferlay J, Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Lam J, Leppert J, Belldegrun A, Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23(3):202-12
   PubMed Web of Science ®Google Scholar
• Pantuck A, Zeng G, Belldegrun A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-52
   PubMed Web of Science ®Google Scholar
• Clifford S, Prowse A, Affara N, Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-9
   PubMed Web of Science ®Google Scholar
• Motzer R, Hutson T, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
   PubMed Web of Science ®Google Scholar
• Barakat M, Meeran K, Bloom S. Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1-18
   PubMed Web of Science ®Google Scholar
• Modlin I, Oberg K, Chung D, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72
   PubMed Web of Science ®Google Scholar
• Turner H, Harris A, Melmed S, Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin D, Bergers G, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Kulke M, Lenz H, Meropol N, Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10
   PubMed Web of Science ®Google Scholar
• Ciuffetti G, Schillaci G, Innocente S, Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003;21:2297-303
   PubMed Web of Science ®Google Scholar
• Hood JD, Meininger CJ, Ziche M, VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu D, Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib [abstract #312]. ASCO GU 2010
   Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee JL, Chang SE, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51
   PubMed Web of Science ®Google Scholar
• George S, Blay J, Casali P, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B, Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71
   PubMed Web of Science ®Google Scholar
• Zhu A, Duda D, Sahani D, Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2007;15:263-8
   Web of Science ®Google Scholar
• Benjamin R, Choi H, Macapinlac H, We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria S, Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9
   PubMed Web of Science ®Google Scholar
• Patel P, Senico P, Curiel R, Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7:24-7
   PubMed Web of Science ®Google Scholar
• Socinski M, Scappaticci F, Samant M, Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010;5:354-60
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar